Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Nabriva Therapeutics plc | a2234062zex-32_1.htm |
| EX-31.2 - EX-31.2 - Nabriva Therapeutics plc | a2234062zex-31_2.htm |
| EX-31.1 - EX-31.1 - Nabriva Therapeutics plc | a2234062zex-31_1.htm |
| EX-23.2 - EX-23.2 - Nabriva Therapeutics plc | a2234062zex-23_2.htm |
| EX-23.1 - EX-23.1 - Nabriva Therapeutics plc | a2234062zex-23_1.htm |
| EX-21.1 - EX-21.1 - Nabriva Therapeutics plc | a2234062zex-21_1.htm |
| EX-10.18 - EX-10.18 - Nabriva Therapeutics plc | a2234062zex-10_18.htm |
| EX-10.17 - EX-10.17 - Nabriva Therapeutics plc | a2234062zex-10_17.htm |
| EX-10.16 - EX-10.16 - Nabriva Therapeutics plc | a2234062zex-10_16.htm |
| 10-K - 10-K - Nabriva Therapeutics plc | a2234062z10-k.htm |
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Nabriva Therapeutics plc (the “Company”) for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Gary Sender, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
/s/ Gary Sender |
|
|
|
|
|
Gary Sender |
|
|
Chief Financial Officer |
|
|
(Principal Financial Officer) |
|
|
|
|
|
Dated: March 16, 2018 |
|